Attention A T users. To access the menus on this page please perform the following steps.
1. Please switch auto forms mode to off.
2. Hit enter to expand a main menu option (Health, Benefits, etc).
3. To enter and activate the submenu links, hit the down arrow.
You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.
Marianne Goodman, MD is the assistant director of the VISN 2 South MIRECC. She directs the Dialectical Behavioral Therapy clinical and research program and suicide prevention treatment program.
Education & Clinical Practice
Yulia Landa, PsyD, MS
Fellowship Director Phone: 718-584-9000 ext. 3703 Email: Yulia.Landa@mssm.edu Dr. Yulia Landa conducts clinical and translational research aimed to improve treatment outcomes for patients suffering from psychosis. Her work focuses on developing and evaluating targeted Cognitive Behavioral Therapy (CBT) interventions for the treatment and prevention of psychosis and identifying critical mechanisms (psychological and neurobiological) of their effects. She has established individual, group and family-based CBT programs for patients experiencing delusions, paranoia and voice-hearing. To facilitate the dissemination of CBT for psychosis Dr. Landa has developed CBT for psychosis training programs and has been teaching clinicians both in the US and internationally.
Lisa Dixon, MD, MPH conducts health services research that focuses on improving the quality of care for persons with SMI including increasing metabolic monitoring, reducing smoking, increasing consumer-driven family involvement in care, and reducing disability among persons who are early in the course of a psychotic illness.
Dr. Corcoran has expertise in schizophrenia, specifically its early stages. She has research funding to study disturbances in sensory processing, language and social cognition across stages of schizophrenia, using MRI, EEG and more recently, automated natural language processing analysis to measure semantic coherence and syntactic complexity. She has used non-invasive brain stimulation for cognitive mapping and to identify targets and circuits for therapeutic neurostimulation. Dr. Corcoran has also studied the role of stress and drug use in onset and symptom expression in schizophrenia, as well as stigma and paths to prevention and recovery.
Vahram Haroutunian, PhD uses postmortem human brain and genetically modified mouse model systems we study the neurobiology of serious mental illness with a strong, albeit not exclusive, emphasis on schizophrenia and molecular biological and genetic techniques.
Stella Dracheva, PhD investigates the role of mRNA editing and epigenetic regulation (DNA methylation and histone modifications) in suicide and other psychiatric conditions using postmortem human brain specimens and/or animal models as well as state of the art methodologies (e.g., RNA-Seq, CHIP-Seq, Infinium 450K Methylation array).
Erin Hazlett, Ph.D. conducts multidisciplinary clinical research using neuroimaging and psychophysiological approaches. Her studies examine the neurobiology of attention and emotion processing abnormalities in schizophrenia-spectrum disorders, personality disorders, and major depressive disorder. She has received funding from the Department of Veterans Affairs, Department of Defense, National Institutes of Mental Health, and private foundations (e.g., Brain & Behavior Research Foundation). Her most recent VA Merit Award grant uses neuroimaging and psychophysiology to examine emotional processing in Veterans at low and high risk for suicide. If you are interested in finding out more about this study call (718) 584-9000 x3605 (Daniel Vaccaro, Clinical Research Assistant). Dr. Hazlett has over 140 peer-reviewed publications and book chapters, is currently a standing member of the Adult Psychopathology and Disorders of Aging (APDA) study section for NIH, and sits on the Editorial Board of the journal Psychophysiology.
Panos Roussos's research is focused on discerning the neurobiology of neuropsychiatric illnesses through understanding the regulation of gene expression. He applies a combination of Molecular Biology and Bioinformatics approaches to tackle these questions.
Philip R. Szeszko, Ph.D. focuses on the role of abnormal white matter in the neurobiology of psychiatric disorders and how these abnormalities may contribute to neuropsychological and functional outcome. He has received funding from the Brain and Behavior Research Foundation, Obsessive-Compulsive Foundation, American Foundation for Suicide Prevention, DANA Foundation and National Institute of Mental Health to conduct brain imaging studies in patients with psychiatric disorders. He has authored or co-authored over 100 peer-reviewed manuscripts and sits on the Editorial Boards of Progress in Neuro-psychopharmacology, Biological Psychiatry and Psychiatry Research: Neuroimaging.
Larry Siever, MD
Retired, VISN 2 South MIRECC Director
Larry Siever, MD was the Chief of Psychiatry and Director of the MIRECC at the JJ Peters VAMC. Dr. Siever studied the etiology of the schizophrenia spectrum and affect and impulsive aggression regulation in serious mental illness.
William Byne, MD, PhD
William Byne, MD, PhD employed a variety of postmortem histological and in vivo neuroimaging techniques to examine brain structure and function in serious mental illness and initiated a pharmacological trial in schizophrenia.
Deborah Kayman, PhD, LMSW
Phone: 718-584-9000 ext.5227
As a social worker, Dr Kayman's research priorities are to promote Veteran empowerment, safety and recovery by examining interventions to (a) prevent crises (e.g., through suicide risk assessment); (b) increase access to peer support (e.g., through new technologies); and (c) impart useful skills (e.g., for problem-solving).
Bruce Levine, MD focuses on the implementation of the full spectrum of evidence based, recovery oriented practice: assessment and diagnosis, treatment partnership, psychotherapies and psychosocial interventions, and psychopharmacological treatments.